Science Explorer Back to mapMap
Discussion
Research facility · Bratislava · Slovakia

Národný Onkologický Ústav

In research, Národný Onkologický Ústav stands highest in Medicine (#14,103 of 14,558 worldwide) and Health Sciences (#16,174 of 16,688 worldwide), over all time.

nou.skROR OpenAlex
World rank, all time
#34,156
of 34,923
Rank in Slovakia
#56
of 60
Research works
361
▼ 80% vs 2018-21
Citations
571
1.6 per fractional work
Top-10% rate
3.0%
all institutions 10.0%
vs its own fields
0.66×
1.00× is exactly expected
Open access
29%
world 40%
International
14%
world 18%
Národný Onkologický Ústav

What is Národný Onkologický Ústav known for in research?

The fields where it stands highest, over all time, ranked among every institution above the floor in each field.

FieldWorld rankWhere that sitsTop-10% rateWorks
MedicineField #14,103 of 14,558 4.3%257
Health SciencesDomain #16,174 of 16,688 4.3%266

Each strip is that field's whole ranked pool, with the notch where Národný Onkologický Ústav sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no average mark, because the average differs by field (from about 6% in Dentistry to 21% in Economics).

Which fields of science does Národný Onkologický Ústav work in?

In all years, 74% of research at Národný Onkologický Ústav is in Health Sciences, 22% in Life Sciences. Its largest fields are Medicine (71%), Biochemistry, Genetics and Molecular Biology (19%), Health Professions (2%). It does 3.1× the world's share of Health Sciences.

Health Sciences: 266 fractional works · 73.6% of its workMedicine: 257 fractional works · 71.1% of its workOncology: 63 fractional works · 17.4% of its workSurgery: 39 fractional works · 10.9% of its workPulmonary and Respiratory Medicine: 37 fractional works · 10.3% of its workEpidemiology: 27 fractional works · 7.5% of its workRadiology, Nuclear Medicine and Imaging: 12 fractional works · 3.2% of its workPublic Health, Environmental and Occupational Health: 9 fractional works · 2.6% of its workPathology and Forensic Medicine: 8 fractional works · 2.1% of its workPhysiology: 5 fractional works · 1.3% of its workGenetics: 4 fractional works · 1.2% of its workNeurology: 4 fractional works · 1.2% of its workPharmacology: 4 fractional works · 1.2% of its workCardiology and Cardiovascular Medicine: 4 fractional works · 1.2% of its workRheumatology: 4 fractional works · 1.1% of its workObstetrics and Gynecology: 4 fractional works · 1.0% of its workDermatology: 3 fractional works · 0.9% of its workEndocrinology, Diabetes and Metabolism: 3 fractional works · 0.9% of its workOtorhinolaryngology: 3 fractional works · 0.9% of its workHematology: 3 fractional works · 0.8% of its workReproductive Medicine: 3 fractional works · 0.7% of its workGastroenterology: 3 fractional works · 0.7% of its workEmergency Medicine: 2 fractional works · 0.6% of its workInternal Medicine: 2 fractional works · 0.5% of its workUrology: 2 fractional works · 0.4% of its workHepatology: 1 fractional works · 0.4% of its workPediatrics, Perinatology and Child Health: 1 fractional works · 0.4% of its workNephrology: 1 fractional works · 0.3% of its workInfectious Diseases: 1 fractional works · 0.3% of its workComplementary and alternative medicine: 1 fractional works · 0.2% of its workOphthalmology: 1 fractional works · 0.2% of its workSmaller subfields together: 2 fractional works · 0.7% of its workHealth Professions: 8 fractional works · 2.1% of its workEmergency Medical Services: 3 fractional works · 0.9% of its workGeneral Health Professions: 2 fractional works · 0.5% of its workOccupational Therapy: 2 fractional works · 0.5% of its workSmaller subfields together: 1 fractional works · 0.1% of its workNursing: 1 fractional works · 0.3% of its workNutrition and Dietetics: 1 fractional works · 0.3% of its workVeterinary: 0 fractional works · 0.1% of its workDentistry: 0 fractional works · 0.0% of its workLife Sciences: 78 fractional works · 21.6% of its workBiochemistry, Genetics and Molecular Biology: 69 fractional works · 19.1% of its workMolecular Biology: 30 fractional works · 8.3% of its workCancer Research: 18 fractional works · 5.0% of its workGenetics: 14 fractional works · 3.9% of its workBiotechnology: 3 fractional works · 0.9% of its workCell Biology: 2 fractional works · 0.7% of its workSmaller subfields together: 1 fractional works · 0.4% of its workImmunology and Microbiology: 6 fractional works · 1.7% of its workImmunology: 5 fractional works · 1.4% of its workSmaller subfields together: 1 fractional works · 0.3% of its workPharmacology, Toxicology and Pharmaceutics: 2 fractional works · 0.4% of its workPharmaceutical Science: 1 fractional works · 0.2% of its workPharmacology: 1 fractional works · 0.2% of its workAgricultural and Biological Sciences: 1 fractional works · 0.3% of its workNeuroscience: 0 fractional works · 0.1% of its workPhysical Sciences: 12 fractional works · 3.4% of its workPhysics and Astronomy: 5 fractional works · 1.3% of its workRadiation: 4 fractional works · 1.2% of its workSmaller subfields together: 0 fractional works · 0.1% of its workChemistry: 3 fractional works · 0.9% of its workSpectroscopy: 2 fractional works · 0.7% of its workSmaller subfields together: 1 fractional works · 0.2% of its workEngineering: 3 fractional works · 0.8% of its workBiomedical Engineering: 1 fractional works · 0.4% of its workMedia Technology: 1 fractional works · 0.3% of its workSmaller subfields together: 1 fractional works · 0.2% of its workChemical Engineering: 0 fractional works · 0.1% of its workEnvironmental Science: 0 fractional works · 0.1% of its workSocial Sciences: 5 fractional works · 1.3% of its workSocial Sciences: 3 fractional works · 0.8% of its workSociology and Political Science: 1 fractional works · 0.4% of its workEducation: 1 fractional works · 0.2% of its workSmaller subfields together: 1 fractional works · 0.3% of its workEconomics, Econometrics and Finance: 1 fractional works · 0.2% of its workArts and Humanities: 1 fractional works · 0.2% of its workBusiness, Management and Accounting: 0 fractional works · 0.1% of its workDecision Sciences: 0 fractional works · 0.1% of its workALL ITS WORKNárodnýOnkologický Ústav361fractional works, all years
Life Sciences22%Physical Sciences3%Health Sciences74%Social Sciences1%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 21 fields, with their numbers
    1. Medicine25771.1%
    2. Health Professions82.1%
    3. Nursing10.3%
    4. Veterinary00.1%
    5. Dentistry00.0%
    1. Biochemistry, Genetics and Molecular Biology6919.1%
    2. Immunology and Microbiology61.7%
    3. Pharmacology, Toxicology and Pharmaceutics20.4%
    4. Agricultural and Biological Sciences10.3%
    5. Neuroscience00.1%
    1. Physics and Astronomy51.3%
    2. Chemistry30.9%
    3. Engineering30.8%
    4. Chemical Engineering00.1%
    5. Environmental Science00.1%
    6. Earth and Planetary Sciences00.0%
    1. Social Sciences30.8%
    2. Economics, Econometrics and Finance10.2%
    3. Arts and Humanities10.2%
    4. Business, Management and Accounting00.1%
    5. Decision Sciences00.1%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 2.25× its world share, 2 worksBiochemistry, Geneti…Immunology and Microbiology: 2.63× its world share, 0 worksImmunology and Micro…Pharmacology, Toxicology and Pharmaceutics: 2.38× its world share, 0 worksPharmacology, Toxico…Environmental Science: 0.15× its world share, 0 worksEnvironmental SciencePhysics and Astronomy: 0.38× its world share, 0 worksPhysics and AstronomyMedicine: 4.31× its world share, 11 worksMedicine1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Medicine, 4.3×. Every wedge is a field page.

All 6 fields, with their numbers
  1. Medicine4.31×11 works
  2. Immunology and Microbiology2.63×0 works
  3. Pharmacology, Toxicology and Pharmaceutics2.38×0 works
  4. Biochemistry, Genetics and Molecular Biology2.25×2 works
  5. Physics and Astronomy0.38×0 works
  6. Environmental Science0.15×0 works

Who are the top researchers at Národný Onkologický Ústav?

Ranked on the quality score, Tomáš Minařík, Andrea Jurečková and Mária Zvaríková lead among researchers whose main affiliation is Národný Onkologický Ústav.

  1. 1 Tomáš Minařík Slovakia · #3,589,254 worldwide 294 citations · 35 works
  2. 2 Andrea Jurečková Slovakia · #4,741,721 worldwide 910 citations · 24 works
  3. 3 Mária Zvaríková Slovakia · #5,057,377 worldwide 67 citations · 16 works
  4. 4 Libor Němec Slovakia · #5,226,312 worldwide 116 citations · 30 works
  5. 5 Lukáš Pochop Slovakia · #5,602,326 worldwide 42 citations · 18 works
  6. 6 Monika Schneiderová Slovakia · #5,653,845 worldwide 65 citations · 24 works
  7. 7 Richard Feranec Slovakia · #5,897,341 worldwide 17 citations · 25 works
  8. 8 Daniel Macík Slovakia · #6,066,123 worldwide 93 citations · 34 works
  9. 9 Iwona Mańka Slovakia · #6,298,952 worldwide 37 citations · 49 works
  10. 10 J Durkovský Slovakia · #6,458,195 worldwide 95 citations · 53 works
All ranked researchers at Národný Onkologický Ústav

What are the most cited papers from Národný Onkologický Ústav?

The most cited paper from Národný Onkologický Ústav is "Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study" (Heather S. Han et al., 2017), with 204 citations. Next come "A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer" (82) and "Safety of everolimus plus exemestane in patients with hormone-receptor–positive, HER2–negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)" (74).

Most cited papers
#PaperReleasedCitations
1 Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study Heather S. Han et al. · Annals of Oncology Open access 28 Sep 2017 204
2 A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer Giuseppe Roberto D’Agostino, Josep-Maria Del Campo, Begoña Mellado et al. · International Journal of Gynecological Cancer 2006 82
3 Safety of everolimus plus exemestane in patients with hormone-receptor–positive, HER2–negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET) Guy Jérusalem, Gabriella Mariani, Eva Ciruelos et al. · Annals of Oncology Open access 30 Jun 2016 74
4 Cancer epidemiology in Central and South Eastern European countries Eduard Vrdoljak, Marek Z. Wojtukiewicz, Tadeusz Pieńkowski et al. · Croatian Medical Journal Open access Aug 2011 60
5 Large cell calcifying Sertoli cell tumor: a clinicopathologic study of 1 malignant and 3 benign tumors using histomorphology, immunohistochemistry, ultrastructure, comparative genomic hybridization, and polymerase chain reaction analysis of the PRKAR1A gene Fredrik Petersson, Stela Bulimbašić, Radek Šíma et al. · Human Pathology 12 Dec 2009 50
All 62 most cited papers, with filters and sorting

Which keywords describe research at Národný Onkologický Ústav?

By fractional works in all years, weighted toward what it does more of than the world: Chemotherapy, Breast Cancer, Radiotherapy, Cancer, Immunotherapy, Clinical Practice Guidelines, Survival Analysis and Cancer Therapy.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Chemotherapy41▲ 16×22 topics
  2. Epidemiology28▲ 1.91×32 topics
  3. Cancer25▲ 4.9×26 topics
  4. Breast Cancer22▲ 21×10 topics
  5. Radiotherapy21▲ 15×11 topics
  6. Immunotherapy20▲ 8.4×12 topics
  7. Clinical Practice Guidelines20▲ 9.7×10 topics
  8. Survival Analysis19▲ 20×6 topics
  9. Cancer Therapy18▲ 8.0×12 topics
  10. Quality of Life18▲ 3.7×10 topics
  11. Metastasis18▲ 15×10 topics
  12. Prognostic Factors17▲ 10×13 topics
  13. Cancer Incidence17▲ 32×4 topics
  14. Precision Medicine14▲ 13×4 topics
  15. Neoadjuvant Therapy14▲ 17×5 topics
  16. Genetic Mutations14▲ 7.2×13 topics
  17. Tumor Microenvironment13▲ 10×6 topics
  18. Diagnosis12▲ 3.4×16 topics
  19. Population-Based Study12▲ 57×2 topics
  20. Surgical Management12▲ 7.5×11 topics
  21. Gene Expression12▲ 5.4×8 topics
  22. Apoptosis12▲ 8.4×10 topics
  23. Immunohistochemistry11▲ 33×3 topics
  24. Molecular Profiling11▲ 27×3 topics
  25. Cancer Survivorship11▲ 53×2 topics
  26. Genetic Susceptibility11▲ 32×3 topics
  27. Metastatic Breast Cancer11▲ 47×2 topics
  28. Clinical Trials11▲ 4.8×7 topics
  29. Targeted Therapy11▲ 14×5 topics
  30. Multiple Primary Cancers10▲ 135×1 topic
  31. Regulation10▲ 4.7×4 topics
  32. Second Primary Neoplasms10▲ 135×1 topic
  33. Molecular Subtypes10▲ 31×3 topics
  34. Cancer Risk10▲ 10×3 topics
  35. Gene Expression Profiling9▲ 25×2 topics
  36. Genetic Testing9▲ 15×3 topics
  37. Molecular Characterization9▲ 13×5 topics
  38. Survival9▲ 18×4 topics
  39. Human Papillomavirus8▲ 19×3 topics
  40. Clinical Management8▲ 11×4 topics

Which research topics does Národný Onkologický Ústav publish most on?

By volume in 2022-now: Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, Cancer Immunotherapy and Biomarkers and Breast Cancer Treatment Studies.

Advanced Breast Cancer T…1Advanced Breast Cancer Therapies: 1 fractional worksHER2/EGFR in Cancer Rese…1HER2/EGFR in Cancer Research: 1 fractional worksCancer Immunotherapy and…1Cancer Immunotherapy and Biomarkers: 1 fractional worksBreast Cancer Treatment …1Breast Cancer Treatment Studies: 1 fractional worksColorectal Cancer Treatments and Studies: 1 fractional worksLymphoma Diagnosis and Treatment: 0 fractional worksGastric Cancer Managemen…0Gastric Cancer Management and Outcomes: 0 fractional worksCancer Treatment and Pha…0Cancer Treatment and Pharmacology: 0 fractional worksTesticular diseases and …0Testicular diseases and treatments: 0 fractional worksLung Cancer Treatments a…0Lung Cancer Treatments and Mutations: 0 fractional works
Pulmonary and Respiratory MedicineOncologyCancer ResearchPathology and Forensic Medicine1 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 1 works
  2. 2 HER2/EGFR in Cancer Research Oncology 1 works
  3. 3 Cancer Immunotherapy and Biomarkers Oncology 1 works
  4. 4 Breast Cancer Treatment Studies Cancer Research 1 works
  5. 5 Colorectal Cancer Treatments and Studies Oncology 1 works
  6. 6 Lymphoma Diagnosis and Treatment Pathology and Forensic Medicine 0 works
  7. 7 Gastric Cancer Management and Outcomes Pulmonary and Respiratory Medicine 0 works
  8. 8 Cancer Treatment and Pharmacology Oncology 0 works
  9. 9 Testicular diseases and treatments Surgery 0 works
  10. 10 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available28.7%not open71.3%

World: 40% of research is openly available.

with international co-authors14.2%domestic only85.8%

World: 18% is written across borders.

How has Národný Onkologický Ústav's research output changed?

Output in 2022-2025 was 80% lower than in 2018-2021.

still counting1990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Národný Onkologický Ústav as a percentage of every work published that year, 0.00000036% in 2024.

still counting0.0010%0.0020%Národný Onkologický Ústav0.000057% in 202519801990200020102020

Fractional works of Národný Onkologický Ústav over all fractional works that year. How the balance of science has shifted.

Other research institutions in Bratislava

All research institutions in Bratislava

Share Národný Onkologický Ústav's ranking

Národný Onkologický Ústav on Science Explorer

A card with Národný Onkologický Ústav's standing and the fields it leads in, for a post or a slide. A link to this page previews as the same card.

Download the card

1200 × 630 PNG, sized for social posts, drawn from the latest snapshot.

Badges for a website1Each links back here and updates with every snapshot

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Národný Onkologický Ústav. Posts are plain text and can be reported.